Maria Lycouris; Investor Relations; Oddity Tech Ltd
Oran Holtzman; Chief Executive Officer, Co-Founder, Director; Oddity Tech Ltd
Lindsay Mann; Global Chief Financial Officer; Oddity Tech Ltd
Yusuf Patel; Analyst; Truist Securities
Mark Mahaney; Analyst; Evercore ISI’s
Corey Carpenter; Analyst; JP Morgan
Dara Mohsenian; Stock Analyst; Morgan Stanley
Andrew Boon; Analyst; Citizens
Operator
Good morning and welcome to Oddity Tech's first quarter 2025 earnings conference call.
Today's call is being recorded and we have allocated time for prepared remarks and Q&A.
At this time I'd like to turn the conference over to Maria Laos, investor relations of for Oddity.
Thank you. You may begin.
Maria Lycouris
Thank you, operator. I'm joined by Oran Holtzman, Oddity's co-founder and CEO,; and Lindsay Drucker Mann, Audity's Global CFO.; Niv Price, Oddity CTO will also be available for the question and answer session.
As a reminder, management's remarks on this call that do not concern past events are forward-looking statements. These may include predictions, expectations, or estimates, including statements about Oddity's business strategy, market opportunity, future financial performance, and potential long-term success. Forward-looking statements involve risks and uncertainties, and actual results could differ materially due to a variety of factors.
These factors are described under forward-looking statements in our earnings press release issued yesterday, and in our most recent annual report on Form 20 filed with the Securities and Exchange Commission on February 25, 2025.
We do not undertake any obligation to update forward-looking statements which speak only as of today.
Finally, during this call, we will discuss certain non-gap financial measures which we believe are useful supplemental measures for understanding our business. Additional information about these non-gap financial measures, including their definitions, are included in our earnings press release which we issued yesterday. I'll now hand the call over to Oran Holtzman.
Oran Holtzman
Thanks everyone for joining our call today. Our Q1 results exceeded our expectations across all metrics and allow us to raise our full year outlook. Once again, in Q125, we beat revenue in EBITDA like we did every single quarter since going public eight quarters in a row.
Revenue grew 27% to $268 million with $52 million of adjusted EBITDA representing a 19.5% of adjusted EBITDA margin and free cash flow of $87 million.
Q1 is our biggest quarter of the year in terms of new acquisition, an important quarter to set the stage for the rest of the year, and we've proved we can deliver also in the current environment exiting Q1 business momentum continued across April and gives us confidence in delivering a strong Q2.
The beauty industry is transforming just like we said it would more than 5 years ago. And all it is a win in this transformation. We have positioned our business to play and lead in the most important vectors of the industry's growth.
Number one is the consumer shift to online, where we're already a dominant B2C platform and number two is the shift towards high efficacy products where we are accelerating our capabilities at labs while continuing to invest in all areas of development.
I have no doubt that these two vectors are by far the most important drivers of the future of the industry. Therefore, we could do to invest massively in technology, data-driven user customization, and science back products.
Our goal is to build one of the biggest beauty companies in the world, full stop. We intend to do it by delivering consumers the best products based on what they need, when they need it, while doing all of this at high scale.
Thanks to the fact that beauty and health are major industries, there are so many areas for us to expand our business into, and we are planning to continue doing so with full power.
Q1 results were another step in achieving this goal. We delivered outstanding financials once again beating our guidance in revenue and profitability. We hear other companies talking about consumer weakness and difficult environment, but as you can see today, we continue to grow fast.
Audit will do approximately $800 million in revenue in 2025, growing from around $300 million in 2022 and around $500 million in 2023. All those years with very healthy profitability and cash generation.
The first quarter is the biggest revenue quarter for us in the year and was the highest base for 2024 to grow from. It's where we turn our user acquisition muscle on adding new users to our platform.
We entered 2025 with a lot of strength with preparation work from 2024 that gave us confidence in our ability to meet our goals.
This allowed us to deliver a massive acceleration to our business and Q1 cells that were once again more than double the sales we delivered in Q4 as planned. We have full control of our business and we proved it once again in Q1.
The advantages of our D2C model are on full display in the current environment. While brick and mortar brands navigate weak slow performance against volatile demand, our business is benefiting from a powerful shift online, a highly agile and assetized model with full visibility and inventory control.
Turning to our 2025 strategic priorities and outlook, first, continue to drive existing brands.
Starting with Il Makiage, which remains on track to meet our $1 billion dollar revenue goal by 2028.
Scheme continues to be a standout success and it's on track to approach 40% of the brand revenue this year.
Skin is a huge growth driver with multiple attractive product categories with bigts, IAOVs, and great replenishment cycles for Imaya to expand in.
As we discussed in our Q4 call, we decided back in 2024 to accelerate our international expansion in 2025. We are putting more strategic focus on internationally, growing our business in the existing markets while continuing to conduct tests in new markets. We are very pleased with the results of Q1 and plan to continue our international scaling.
We remain bullish about our international business which show greater in economics. Just to put it in perspective, for our largest competitors, less than 30% of their business is in the US. For us, the US is currently around 80%. This ability to get scale internationally is a massive engine for all.
If in the past we said this is a great option for us to grow in Q1, we have started to prove it.
Products, new categories, new brands, new markets, new users versus existing users, all of those muscles are, as they call it, growth drivers on demand.
We optimize all of them to preserve our high profitability.
At every moment we decide where it makes more sense to scale, which makes the business so strong and profitable, enabling us to continue to deliver the skills combination of scale, growth and profitability.
Child, our second baby, continued its strong growth in its 3rd year since launch.
It remains in its early stages, and we believe it has a huge runway in front of it. It is on track to cross the $200 million revenue mark this year with very healthy margins again for a 3 year old brand.
Our teams have been focused on optimization of unit economics while we drive scale. We continued our brand investment in Q1 with the second drop of spoiled child's collaboration with fashion designer Jeremy Scott.
Second is our new brand launches. We are very bullish on the opportunity for both brands 3 and 4. In addition to growth, building new brands allows us to maintain a startup DNA, which is extremely crucial in my view.
Brain 3 is on schedule to soft launch in Q3 with formal lounge in Q4. With every muscle we build, I want to believe we are getting better with time. And for Brent 3, I can tell you that based on the level of complexity, both technology and product offering, our preparation, and our testing, I am more excited than ever before to see it live and we will do whatever it takes to win Brand 3 categories.
As a reminder, Brentre is the telehealth platforms, starting with medical grade skin and body issues that will expand into new medical domains over time. Almost a third of the global population experience skin conditions and diseases, including acne, eczema, sacea, and others. Additionally, many individuals report that their skin conditions significantly affect their emotional well-being, which made this mission even more important to what it is a company.
We see it also in our user base. Skin and body concerns are a broad pain point for our users. Around half of them are suffering from at least one of these issues.
Similar to spoiled child, rent is fully did to same.
Our product offering is very compelling in our view. It includes access to prescription and OTC treatments, enabling full personalization to user profiles, types, and severities.
Computer vision is a key component of venting. Our Israeli R&D teams are working on developing it for the past 3 or 4 years with very large investment.
One example is our ARIC grading algorithms trained with dermatologist input that delivers 94% agreement with expert dermatologists tagging in internal validation studies.
Another is our acal lesion localization and classification models that allow us to identify, map, measure, and classify lesions with 93% recall, meaning the model correctly identifies 93% of true acne lesions.
We've also developed a hyperpigmentation detection model that segments and classifies discoloration with 84% matching accuracy based on dermatologists label data.
We have introduced a predictive view algorithm trained on user data and powered by Gen AI to visualize expected skin improvements, boosting motivation and trust through personalization progress reviews.
Our vision tools are crucial to winning this category. It allows us to assess user progress on high frequency basis, supporting their progress when you combined with a professional medical evaluation.
We believe that we have the ability to change this category with any offering. As for telehealth infrastructure, the infrastructure we are building to support prescription and comping for brainre today is a jumping off point for us to expand into additional medical domains beyond skin and body post launch.
Rainfall continues to be on track for 2026, a big opportunity for us with more updates to come.
Third is audity labs where we continue to increase our investment, growing our teams, expanding our internal R&D, as well as outside partnerships to accelerate discovery at high scale. Our mission at lab is to drive massive innovation by bringing real science at high scale to our industry and turbocharging distribution through Audity's online platform. Our scientists and teams are actively developing both short and long-term innovation in skin, color, hair, and body to beat the efficacy of existing products in those spaces.
We are developing proprietary molecules for both brands 3 and 4 in the short term while also working on longer term developments with huge market potential.
As we said before, lab takes time and we don't need it to meet our financial targets, but if we do it right, it's a complete game changer for us. It can take the company to a different level and almost unlimited size.
I believe we are in a race for high efficacy science based products, and we do all we can to win this race.
Lastly is our tech capabilities where we continue to invest in order to deliver the best experience for our customers online and to enable profitability at high scale. We are deploying both dollar and focus on developing new tech products and improving existing ones to drive improvement in our business. We are very focused roadmap and we work at high pace to meet our goals.
Before I hand it over to Lindsay, I want to close with some thoughts about the current environment.
We see this moment as a massive opportunity for. Our DNA and business model allow us to play full offense in times like today, and this is exactly what we do. We operate in a huge and attractive global town which has proven time and time again to be resilient in economic downturns. The structural changes in the industry, including the growth of online, are only strengthening audit, and as you can see in our Q1 results and Q2 outlook, our business performance remains very strong.
From where we stand today, our advantage can only grow in times like this. Moments like this are when category leaders are built, and this is our intention. With that, I will turn it over to Lindsay Drucker Mann.
Lindsay Mann
Thanks, Oran.
Turning to our.Q1 results, which I'll refer to on an adjusted basis, you can find the full reconciliation to GAAP in our press release.
Oddity delivered another record breaking result for our most important quarter of the year. Recall that in Q1 we set the tone for the full year by ramping up our acquisition spend, which leads to high visibility backlog of repeat that drives our full year financial results.
We came into Q1 this year off a large base from our strong performance in 2024 and delivered an outstanding result on top of it. Net revenue grew 27% to $268 million exceeding the high end of our guidance for 24% growth to $262 million. The strength was driven by both IL Makiage and spoiled child.
Net revenue growth was driven primarily by increased orders, while average order value increased 4% year over year. Average order value was driven in part by a mix to higher priced products like skin. It was offset in part by faster growth in international markets, which today tend to be lower AOV due to their earlier development stage. We continue to expect border growth will be the primary driver of our revenue growth going forward.
Our Q1 results stand in contrast to concerns we hear about softness and other beauty businesses, including both retailers and wholesalers. This is directly related to our unique model, our exposure to our online, which is the most attractive growth channel for the beauty category today, and our very high repeat rates as our customers continue to come back with high satisfaction to our products and brands. Repeat revenue is the largest part of our business, exceeding 60% of total revenue in 2024 and increasing as a percent of our business again so far in 2025.
Moving down the P&L gross margin of 74.9% expanded 116 basis points year over year and exceeded our guidance for 72%. The upside was driven in part by cost efficiencies and product mix. We delivered adjusted EBITDA of $52 million and adjusted EBITDA margin of 19.5% above the high end of our guidance for $50 million.
We continue to ramp up our planned investments in future growth initiatives, including Brand 3, which is planned for soft launch in Q3 and full launch in Q4, Brand 4, which is planned for launch next year, and Oddity labs.
We delivered adjusted diluted earnings per share of $0.69 compared to our guidance of between $0.61 and $0.63. In 11, we once again delivered excellent free cash flow of $87 million. Our free cash generation and cash conversion is a clear reflection of the strength and quality of our business model.
This strong cash generation allowed us to exit the quarter with $257 million of cash equivalents and investments on our balance sheets and zero debt. Between the cash on our balance sheet and our new undrawn $200 million dollar credit line that we closed in January, with ample liquidity to operate our business and deploy opportunistically.
We expect the current volatile market backdrop will create new opportunities for us to put our strong balance sheet to work, and we're actively looking for those. This could take the shape of brand and business acquisitions that plug into our platform or acquisitions of technology and teams that advance our capabilities. Even with our enthusiasm for these opportunities, we're extremely disciplined about what we would pursue, and our internal hurdle rates are high.
Turning to our outlook for 2025, Q2 is off to an excellent start with good momentum through the end of April. The size of the first quarter combined with the high predictability of cohort repeat gives us good visibility to once again exceed our long-term algorithm of 20% revenue growth and 20% adjusted EBITDA margins. We now expect full year revenue growth will be between 22% and 23%, or between $790 and $798 million.
We're raising our gross margin outlook to 71% for the full year from 70% prior, and this incorporates our latest view on tariffs and supply chain impact.
We're also raising our adjusted Outlook to $157 to $161 million and our adjusted EPS Outlook to $1.99 to $2.04 which assumes a 20% tax rate and no share buyback.
As we've discussed before, our EBITDA outlook includes significant increased investments in future growth initiatives, including our new brands and oddity labs, but with no revenue contribution benefit from these efforts.
Finally, let me take a moment on tariffs. The ultimate tariffs and trade policies are very much fluxed and our teams are working aggressively to mitigate the impact on our P&L.
Relative to other consumer companies, we're very well positioned. We have an attractive gross margin structure, limited exposure to China directly, a robust and flexible supply chain, and great relationships with our global suppliers. We expect to incur between 50 and 100 basis points of tariffs and related costs on our gross margin in 2025, some of which will be offset by internal efficiencies and other mitigation efforts.
Based on the information we have today, we expect these headwinds will be manageable, allowing us to increase both our gross margin and adjusted the dollar outlook for the full year. It is too soon to give specific guidance on 2026, but our current expectation is for the impact of tariffs and trade policies to be similarly manageable, and we have no concerns today about achieving our long-term algorithm of 20% revenue growth at a 20% adjusted margin. With that, I'll hand the call back for questions.
Operator
Thank you. Ladies and gentlemen, we will now be conducting a question and answer session (Operator instruction).
Yusuf Patel, Truist Securities.
Yusuf Patel
Thank you very much and good morning. Also so congrats on a very solid quarter, especially considering the macro guys. I have two quick questions one on international or on I think just as a follow up to your comments.
How much of a, of a, of lift the international contribution to the quarter because it was really only on the last earnings call that you guys started talking about maybe accelerating an international spoiled child now, starting to be expanded into international markets and, secondarily. The FTC recently passed the click to cancel rule. I was wondering how you guys are thinking about that as potentially impacting the business or not.
Thank you very much.
Oran Holtzman
Good morning, Yusuf.
Thank you very much for joining. Look, last year we made a strategic decision to push international harder in 25, which meant scaling markets. We are already in and while we are also pushing larger scale tests in new markets. And we talked about in Q4.
That's the good thing about our business, like everything is prepared and once we want to pull that trigger, everything is ready. International has been a core part of our plan, especially for taking IL Makiage to $1 billion dollar revenue target by 2028, so we need it, and it did great in Q1. It only proves to us and to me how big these markets will be for us, and we expect that they will deliver great growth for us in the future.
And to your question, both US and international grew double digits in Q1. International is still less than 20% of the business. So by definition we needed high growth in the US, but we are very bullish, and we'll continue to push it.
Lindsay Mann
Thanks Youssef. On click to cancel this piece of regulation has been out for a while. Our teams have already done a lot of work on it. Ultimately we don't see much impact at all. Obviously we don't know what the final implementation will look like, but we're already in very good shape in terms of how we approach. Subscriptions and cancellations.
Everything for us is opt in rather than opt out, which is different than many direct to consumer businesses, including the likes of Amazon, for example. Cancelation is fully self-serve online and straightforward. We have a great team of customer service reps that support out, thousands and thousands and millions of orders, across the year and of all the changes we've tested a number of different changes depending on your interpretation of the ruling, and none of them have a major impact on our business. So we expect this to be a non-sue for us.
Yusuf Patel
Okay, that's super helpful thank you and congrats again.
Operator
Thank you. The next question comes from Mark Mahaney with Evercore ISI. Please go ahead.
Mark Mahaney
Okay, thanks. I think, Lindsay, you talked a little bit about the gross margins. Could you just double click on that a little bit more and. The biggest factors that are causing gross margins to rise, where do you think they can go? Is it, has something changed in how you think about where your gross margins can go over the next 3 to 5 years, just what efficiencies you've been able to ring out, or is it just scale that's allowed those gross margins to rise?
Thank you.
Lindsay Mann
Thanks, Mark. So gross margin was a nice highlight for us in the quarter, but as we said before, and I just want to reiterate, gross margin is not a metric or KPI that the teams are benchmarked to rather than gross margin, we focus on DC margin or contribution margin, which is basically gross margin after media spend, and it's important because there are some products that might have a lower gross margin profile but better frequencies.
And if they deliver. A superior DC margin, we're happy to make that trade, and we never want to constrain our teams in going after the right opportunities as it relates to LTV and DC margin in favor of a gross margin outcome. Obviously it's a metric that that my team looks at a lot and obviously as it relates to cost efficiencies, it's something the team has been very focused on.
And so over the last few years, as you've seen us overdeliver on gross margin, some portion of that has been really Great execution from our teams across a number of areas. I mean, truly blocking and tackling and parts of supply chain, logistics, fulfillment, etc.
So, that was a support for us in the quarter. But also when we issue our gross margin guidance, we like to give the teams a lot of latitude to chase after the types of products that make sense again from a DC perspective and so that we're not disappointing street expectations. So it's been a line that we've historically guided conservative.
That being said, as we look longer term, we've talked about the right kind of run rate for our gross margins to be more in the high 60s kind of range. So you should not expect, and we are not committed to maintaining the 71% gross margin profile that we're achieving this year. However, we are very committed to maintaining adjusted EBITDA margins, which is the right metric for you guys to focus on of 20% or more.
Oran Holtzman
One last thing that I will add.
When we decide to push skin has high AOA and therefore high gross margin, and again, those things can change based on our decision of what product we want to push into the market.
Mark Mahaney
Thank you very much.
Operator
Corey Carpenter, JP Morgan
Corey Carpenter
Thank you. Good morning. I had to excuse me, on brand 3, or on, you mentioned you're more excited than ever to see it live. Could you just expand on what you're seeing? I think last quarter you said you had 100 test groups that were in action.
And then secondly, Lindsay on tariffs, thank you for the, gross margin quantification. Could you just talk about the levels of tariffs, maybe specifically that you're assuming that's embedded in that guidance.
Thank you.
Oran Holtzman
Just to make sure, Brand 3, right?
Corey Carpenter
Yes.
Oran Holtzman
Cool look, we are working on Brand 3 more than close to 4 years, so when I say that I'm excited, it means that I have the reasons to be excited. And we tested a lot.
The most important part was to be able to build the dual technology and we are in a better shape than what I hope to be for launch.
I don't need to justify that this category is huge. We already know that more than 1/3 of them of the US consumer is suffering from one of the areas that we are about to tackle with this brand launch, so I have no doubt that demand is there, and I also know that.
The reason why we developed this brand is because we saw very poor options out there for the consumer. So if we have the right product and we have the right technology and the market is there, and I have no doubt that we can that we can win.
One important part that was also very complex for us that now because we are closer to launch, I can see it is the product range is the widest product range that we ever launched both Odyssey and prescription.
And we built infrastructure and it's multi-category and everything was tested at high scale to make sure that we have this like both the matching works well and also a very strong product. So that's why I'm saying that we are in good shape because we saw some tests and things look great.
Lindsay Mann
Cory on the tariff question as we talked about in my prepared remarks. In 2025 we expect there to be something like a 50 to 100 basis point impact on our gross margin from the flow through of tariffs in 2025. We described this as manageable and actually we hope that we can bring that overall impact lower and then looking into 2026, while we're not giving explicit guidance.
We also see the level of pressure as manageable and nothing that would get in the way of us delivering on our long term algorithm of 20% revenue growth at adjusted EBITDA margins. The current contemplated in our guidance is the current level of tariffs that have been announced. Obviously this is a moving target, but in our assumptions it's a fully loaded amount for China plus the 10% on Europe.
However, a range of 50 to 100 basis points would still be correct, even if you saw a doubling of European tariffs after the 90 day pause. And I just want to reiterate to everybody, what we're truly in. A fortunate position because our exposure is just not that big.
We have very high gross margins as a starting point, 71% for this year, and that just means from a numbers basis, even in a higher tariff scenario, it's just a smaller proportion of the cost-based, smaller proportion of the revenue base, and of course our exposure to the most challenging areas in particular China is limited because most of our costs come out of Europe.
Corey Carpenter
That's thank you.
Operator
Thank you.
Dara Mohsenian, Morgan Stanley
Dara Mohsenian
Hey, good morning.
So, first, just one clarification on the increased international emphasis, would you say is that more related to scaling existing markets or is entering new markets a big piece of that, either in 2025 or longer term as we think about that increased emphasis and maybe specifically how spoiled child fits into that and then just obviously your balance sheets in great shape.
Can you just update us on how big a priority acquisitions might be and when you think about acquisitions, what's the strategic lens you're most focused on? Is it more technology? Is it more brands? What areas are you are you most focused on when you think about M&A going forward and potentially areas that they could add value?
Oran Holtzman
Sure I am international is a big opportunity for us, as we said, it's only 20% for I and in early testing, which is close to nothing for spoiled child, while for our competitors it's around 70% of their business, so the opportunity is huge.
And over the last few years we've made investments in preparing those markets, mostly in Europe, but also selectively outside of Europe to position us to scale. And for each market we have totally localized experience and we have tested live in market thousands of order and only after we see like those strong metrics, then we decide to launch markets we are in now after official launch are US, Canada, UK, Germany, Australia, and Israel.
New market that we already tested at large scale and contributed already revenue of for example France, Italy and Spain, but we recently also began testing in some large developing markets and the results are very strong. And therefore, we are very bullish. As for M&A, I would just say that we are looking to find things we don't have. Okay, that's the truth, and we know how to build brands.
If we see a brand that has a very strong product or something that we don't have internally or we take. 5 or 10 years to build then it makes sense. Other than that, mostly around biotech and AI. Those are the areas that I'm spending time on and we believe that this is the future of the industry. This is where we need to lean in even further.
Lindsay Mann
I just wanted to add one more thing there to your to the first question, which is to talk about, part of why we feel so bullish about 2025 is not only just that the category we operate in has historically been quite resilient, but just how diversified our business is today, than even before, multiple product categories and now multiple markets we can grow into.
To and a very agile model that allows us to identify and chase into demand. So if you think about a few years ago we had one brand with Il Makiage and one category in color and just one market essentially in the US. By the end of this year we're going to have 3 brands in 4 categories and in several different markets, and this just allows us a lot of flexibility on growth and profitability.
Dara Mohsenian
Alright thanks guys.
Operator
Andrew Boon, Citizens.
Andrew Boon
Thanks so much for taking the question. Lindsey, I wanted to ask about [SGNA]. Is there any way that you can pull back the curtain and help us maybe understand the advertising component of [SGNA] and kind of the growth that you saw maybe year over year? Additionally, I would love to understand also the efficiency of the advertising spend.
I think at IPO you guys were targeting kind of a [3X]12 month payback period. Can you just update us on where you are today on that? That would be helpful. And then Ron within your prepared comments, it sounded like you talked about the potential optionality within having now a telehealth infrastructure platform. Can you speak to that? What else may be possible as you guys do have now a wider kind of infrastructure base for future brands? Thanks so much.
Lindsay Mann
Great, Andrew, I'll start with your first question. So, we never talked about a target of 3X, so we had said around the time of our IPO was that our 12 month LTVDAs were around 3X, but it's not explicit target for us. Obviously what we care about, what we've talked about the most is maintaining that 20% adjusted EBITDA margin which we've been able to do handily even as we're ramping up investments in a lot of these future growth initiatives to dig into where the investments for the future are when we talk about that.
First of all, just to reiterate. That we have a lot of, we have a big commitment to maintaining these investments in the future. We don't see a reason to deliver higher than a 20% even on margin, especially because we really believe these investments can be massive on lots for our business. Performance, the TAM is just way too big and the opportunity too large for us not to reinvest.
And just as a reminder, we generate very high returns on capital. The best place for an additional $1 for us has been reinvesting in the business and we'll continue to do that. So it's areas like new brand development, we have a lot already in the base, and that will be ramping across the year behind brands 3 and 4.
Both brands already have nice sized teams in place, although we'll be adding to them. These are on our payroll and of course part of the numbers you see today, labs, which we're continuing to build as a large investment, we're building systems, teams.
A lot of infrastructure, a lot of tech. We already have over 60 scientists in labs in Boston. This is really the best example of our mindset for the next two to three years. This is mostly going to be expensive, but we feel a lot of conviction that will pay off in the future.
And then of course tech, it continues to be the largest team in the company, super important for us to continue reinvesting to preserve our competitive advantage. Developing new tech products that we will use to drive conversion, LTD and satisfaction. That's really the bread and butter of the business.
You saw us with an Apple hire earlier this year with Bionic. We're continuing, there's just a lot more that we can do with our tech platform that we continue to invest. So I think those are kind of the key buckets of SGA investment, of course, in addition to continuing to drive our marketing spend year over year along with our revenue.
Oran Holtzman
I will address the telehealth part. Like the way that we think about things, we build capabilities and then we expand and we build tech and data. It didn't make sense to have just one brand or for one category, so we did spoil child, now we're building more brands and to use the same shared mode.
And the same way that we view it as for our telehealth platform, once you have the infrastructure, once you have the doctors, once you have the ability to ship prescription products, then you're in a very good shape to expand and for competitive reasons, obviously I cannot show which areas, but you can imagine that this potential is massive for us. It took us years to build it, but it's something that I wanted to do for a long time.
Dara Mohsenian
Thank you.
Operator
Thank you. This concludes a question and answer session. I would now like to hand the conference over to Oran Holtzman for closing remarks.
Oran Holtzman
Thank you very much guys for meeting us today and see you next quarter.
Operator
Thank you. This concludes today's teleconference. You may disconnect your lines at this time.
Thank you for your participation.
